Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(63%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
38%
Ph phase_3
1
13%
Ph phase_1
4
50%

Phase Distribution

4

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(6)
Completed(2)

Detailed Status

Recruiting4
Completed2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (50.0%)
Phase 23 (37.5%)
Phase 31 (12.5%)

Trials by Status

completed225%
not_yet_recruiting113%
active_not_recruiting113%
recruiting450%

Recent Activity

5 active trials
Showing 5 of 8
recruitingphase_3

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

NCT07139873
not_yet_recruitingphase_1

A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)

NCT07454863
active_not_recruitingphase_2

DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

NCT06539195
recruitingphase_2

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

NCT07154264
recruitingphase_2

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

NCT06539182
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07139873Phase 3

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Recruiting
NCT07454863Phase 1

A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)

Not Yet Recruiting
NCT06539195Phase 2

DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

Active Not Recruiting
NCT07154264Phase 2

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Recruiting
NCT06539182Phase 2

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Recruiting
NCT05824585Phase 1

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recruiting
NCT05844956Phase 1

A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Completed
NCT05176873Phase 1

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8